What You Should Know:
- Faro Health, a cloud-computing company that is developing digital infrastructure for smart clinical trials raises $20M in Series A funding led by General Catalyst to help scale the digital transformation of clinical trials––essentially making it easier and quicker for drug developers to greatly reduce the cost and time of trials.
- The round also included participation from previous investors Section 32, Polaris Partners, Zetta Ventures, and Northpond Ventures.
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Why Researchers Should Explore New Apps of Machine Learning
As the amount of real-world data (RWD) in the pharmaceutical industry continues to grow, so does the usage of machine learning (ML) to analyze that data and gain insights. In fact, in a recent survey, 95% of life sciences executives said they expect to utilize ML in the next few years to generate real-world evidence (RWE) from this data.
With such a large and growing volume of data available, researchers may be wondering how they can take advantage of all of it to enhance and expand the
Read More
2023’s Biggest Pharma Cybersecurity Threats to Watch
Due to the recent growth of the pharmaceutical industry, the value of highly-sensitive data stored in pharmaceutical systems and the degree of the potential damage that cyberattacks on the industry can cause, it is safe to say that pharma could be one of the most targeted industries by cybercriminals in 2023. Ransomware, phishing attacks, business applications and third-party vendors will be some of the biggest threats to this key vertical as we approach the new year.
RansomwareThe threat of
Read More
M&A: Accenture Acquires Life Sciences Consulting Firm Bionest
What You Should Know:
- Today, Accenture announced it has acquired Bionest, a strategy and consulting firm dedicated to addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy (CGT), and rare diseases. Terms of the transaction were not disclosed.
- Scientific and technological advancements are creating breakthroughs for patient health,
Read More
M&A: Science 37 Acquires Vault Health’s Life Sciences Platform
What You Should Know:
- Science 37 Holdings, Inc., the industry-leading Metasite announced it has acquired life sciences platform from Vault Health, a national leader in remote diagnostics and COVID testing, to further enhance clinical trial workflow orchestration and data interoperability capabilities of the Science 37 platform.
- The asset purchase accelerates Science 37’s existing development plans for workflow features such as advanced scheduling and investigational product tracking,
Read More
ProKidney Taps CVS Health Clinical Trial Services for Precision Recruitment
What You Should Know:
- CVS Health Clinical Trial Services and late clinical-stage cellular therapeutics company ProKidney Corp. today announced a collaboration to enroll patients with type 2 diabetes and chronic kidney disease into the proact 1 (REGEN-006) Phase 3 clinical trial of REACT®.
ProKidney’s lead product candidate, REACT® (REnal Autologous Cell Therapy), is a first-of-its-kind, patented, autologous cellular therapy with the potential to not only slow and stabilize the
Read More
Curebase Launches Remote First DTx Research Platform
What You Should Know:
- Curebase, a company committed to democratizing access to clinical trials, announced the release of its integrated software and services package for digital therapeutics (DTx) trials that accelerates enrollment and allows sponsors to launch their studies faster.
- Available now, the new Curebase offering includes the first one-stop-shop decentralized clinical trial (DCT) platform bundled with site and trial execution services for the DTx market.
Making
Read More
Paradigm Launches with $203M to Improve Clinical Research Access
What You Should Know:
- Paradigm, a healthcare technology company focused on improving access to clinical research for patients, launched with $203 million in Series A funding.
- Conceived by ARCH Venture Partners, and co-incubated by ARCH and General Catalyst, Paradigm is rebuilding the clinical research ecosystem by creating a technology-forward clinical trial platform that enables equitable access for all patients by enhancing trial efficiency and reducing the barriers to participation
Read More
Boosting Clinical Trial Recruitment Requires Humanity – and Technology
Clinical trials should be a time of promise for better patient outcomes, as they explore new ways to potentially help patients suffering from a variety of conditions. Instead, this phase of treatment development is often met with exasperation as patients, researchers, and drug developers deal with the many barriers to clinical trial recruitment and access.
There are two central – and intrinsically linked – problems with the current state of clinical trial recruitment in the U.S.:
Read More
Caris Life Sciences Raises $400M to Advance AI-Driven Molecular Profiling to Revolutionize Cancer Care
What You Should Know:
- Caris Life Sciences® (Caris), the a molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the company has closed a senior secured term loan providing up to $400M in capital from OrbiMed and Braidwell. With this funding, Caris has raised approximately $1.7 billion in capital since 2018.
- Caris' comprehensive molecular profiling approach precisely analyzes DNA (Whole
Read More
